PMID: 11315259Apr 24, 2001Paper

High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer

Journal of Cancer Research and Clinical Oncology
P BojkoS Seeber

Abstract

We report the results of high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation in twenty-one patients with primarily advanced or relapsed ovarian cancer. Twenty-five women underwent stem cell collection, and 21 were finally treated with different regimens of HDC containing cyclophosphamide, etoposide, carboplatin, and treosulfan. The patients received cyclophosphamide +/- cisplatin and cisplatin + paclitaxel, respectively, followed by G-CSF (n = 24) or GM-CSF (n = 1) for stem cell mobilization. A mean of 7.2 +/- 6.1 x 10(6) CD34+ cells per kg bw were collected. Thirteen patients received double transplants and one patient received a triple transplant. The median age was 47 years (range 24-61 years) and the mean number of prior regimens was three (range 1-8). Engraftment occurred on time in all patients and there was one treatment-related death resulting in an overall mortality rate of 4.8% among the 21 patients treated with HDC. The response rate was 72% (48% CR, 24% PR) and the mean time to progression and overall survival after HDC were 7 and 32 months, respectively. HDC could be performed safely in patients with advanced ovarian cancer. However, even with a high response rate, the duration of response ...Continue Reading

Citations

Feb 2, 2002·Current Oncology Reports·Prema P Peethambaram, Harry J Long
Sep 15, 2010·Expert Opinion on Investigational Drugs·Franciszek K GłówkaJacek Wachowiak
Nov 21, 2007·Dermatologic Clinics·Rachel E Sanborn, David A Sauer
Jan 18, 2006·Experimental Hematology·Fredrik SjööMoustapha Hassan
Mar 6, 2003·Journal of Cancer Research and Clinical Oncology·M HänelF Kroschinsky
May 9, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R NowrousianS Seeber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.